CytomX Therapeutics $58.3 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Precigen $34 million follow-on offering
We advised Precigen on the SEC-registered offering
Generation Bio $237 million at-the-market offering
The shares are listed on Nasdaq
Bansk Group $1.5 billion going-private acquisition of PetIQ
We are advising Bansk Group on the transaction
Revolution Medicines $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
AC Immune $80 million at-the-market offering
We advised AC Immune on the offering
Clariane €92 million reserved capital increase and €237 million rights offering
We advised Clariane on its refinancing transactions
IDEAYA Biosciences $302.5 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $230 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
InflaRx $75 million at-the-market offering
The shares are listed on the Nasdaq Global Market